Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295834 | 0.81 | NAAA (0.39) | ALDH1A1POLBKDM4EMAPTNAAA | |
| SCHEMBL11379262 | 0.81 | NAAA (0.39) | ALDH1A1POLBKDM4ENAAASMN1; SMN2 | |
| SCHEMBL10008673 | 0.80 | MAOB (0.47) | ALDH1A1POLBKDM4EMAPTTP53 | |
| SCHEMBL1060088 | 0.79 | ALDH1A1 (0.40) | ALDH1A1POLBKDM4EMAPTTDP1 | |
| SCHEMBL1007733 | 0.78 | LMNA (0.42) | ALDH1A1POLBKDM4EMAPTNPSR1 | |
| SCHEMBL1008889 | 0.78 | POLB (0.42) | ALDH1A1POLBKDM4EBCAT1TDP1 | |
| SCHEMBL10314907 | 0.76 | ALDH1A1 (0.41) | ALDH1A1POLBKDM4EBCAT1MAPT | |
| SCHEMBL335184 | 0.76 | ALDH1A1 (0.41) | ALDH1A1POLBKDM4EBCAT1TDP1 | |
| SCHEMBL1010296 | 0.76 | KDM4E (0.41) | ALDH1A1POLBKDM4EBCAT1TDP1 | |
| SCHEMBL16879533 | 0.76 | ALDH1A1 (0.41) | ALDH1A1POLBKDM4EBCAT1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-22 | — | — | US | disclosed |
| US-9950062-B2 | Compounds and compositions as TLR activity modulators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-04-24 | — | — | US | disclosed |
| CN-102844047-B | Immunogenic composition containing TLR active regulators | 诺华股份有限公司 | 2017-04-05 | — | — | CN | disclosed |
| US-9597326-B2 | Benzonapthyridine compositions and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-03-21 | — | — | US | disclosed |
| EP-2473508-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9045470-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2015-06-02 | — | — | US | disclosed |
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | disclosed |
| US-8895577-B2 | Compounds and compositions as TLR activity modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-11-25 | — | — | US | disclosed |
| EP-2459216-B1 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| EP-2473508-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2012-07-11 | — | — | EP | disclosed |
| EP-2459216-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011130379-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011049677-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-28 | — | — | WO | disclosed |
| CN-102015651-A | Compounds and compositions as TLR activity modulators | IRM LLC | 2011-04-13 | — | — | CN | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| WO-2011027222-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | ALDH1A1 4804/4885POLB 3038/4885KDM4E 2884/4885 |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | ALDH1A1 4804/4885POLB 3038/4885KDM4E 2884/4885 |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | ALDH1A1 4772/4885POLB 3962/4885KDM4E 1503/4885 |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | ALDH1A1 4543/4885POLB 2979/4885KDM4E 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.